BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 10690544)

  • 1. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
    Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
    Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
    Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
    Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
    Ebert W; Muley T; Trainer C; Dienemann H; Drings P
    Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in patients with small cell lung cancer].
    Song LH; Song XR; Zhang XQ; Qi JL; Li XJ; Tian H; Bu B
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):413-6. PubMed ID: 15355646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
    Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
    Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The "neuron-specific enolase" tumor marker as a prognostic indicator in small cell bronchial carcinoma].
    Hoster M; Kirchheiner T; Rühle KH
    Pneumologie; 1995 Aug; 49(8):470-4. PubMed ID: 7479642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The changes in serum neuron-specific enolase in patients with small cell lung cancer].
    Taitou H; Sakurai M; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ookura H; Saijo N
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3046-9. PubMed ID: 2823722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
    Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
    Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
    Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer].
    Zych J; Szturmowicz M; Sakowicz A; Słodkowska J; Załeska M; Radzikowska E; Załeska J; Jodkiewicz Z; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 2002; 70(5-6):278-83. PubMed ID: 12518626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
    J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of tumor markers in the management of small cell lung cancer].
    Ariyoshi Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.